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Abstract. Objectives: The most impor-
tant renal complication of systemic sclerosis 
(SSc) is scleroderma renal crisis (SRC). Many 
patients demonstrate less severe renal compli-
cations, most likely associated with reduced 
renal blood flow and a consequent reduc-
tion in glomerular filtration rate (GFR). The 
mechanism of this slowly progressive form of 
chronic renal disease is unclear. The aim of 
this study was to evaluate GFR by the Chronic 
Kidney Disease Epidemiology Collaboration 
(CKD-EPI) and the 7-variable Modification 
of Diet and Renal Disease (MDRD) equa-
tions in SSc patients and to correlate esti-
mated GFR (eGFR) with clinical variables 
of the disease. Methods: 105 unselected and 
consecutive patients with SSc were enrolled. 
Serum creatinine was measured in all patients 
and GFR was estimated by 7-variable MDRD 
and CKD-EPI equations. Nailfold videocap-
illaroscopy was performed in all patients. 
Results: The mean value of eGFR evaluated 
by both 7-variable MDRD and CKD-EPI 
was significantly different (p < 0.0001) in the 
three capillaroscopic groups and correlated 
negatively with the severity of capillaroscopic 
damage (early: 95 ± 16 mL/min and 101 ± 12 
mL/min, active: 86 ± 25 mL/min and 95 ± 17 
mL/min, late: 76 ± 21 mL/min and 82 ± 21 
mL/min). The mean value of eGFR evaluated 
by 7-variable MDRD (97 ± 23 mL/min vs. 
74 ± 15 mL/min, p < 0.0001) and CKD-EPI 
(0.83 ± 0.20 mL/min vs. 0.68 ± 0.10 mL/min, 
p < 0.0001) was significantly higher in SSc 
patients without history of digital ulcers than 
in those with. Conclusion: We can conclude 
that in SSc patients without renal involve-
ment, eGFR decreases with the progression of 
digital vascular damage.
Introduction
Several patterns of renal pathology are 
recognized in patients with systemic sclero-
sis (SSc); almost all involve vascular abnor-
malities. The most important renal complica-
tion of SSc is scleroderma renal crisis (SRC). 
Many patients demonstrate less severe renal 
complications (e.g., abnormal renal vascular 
resistance indices), most likely associated 
with reduced renal blood flow and a conse-
quent reduction in glomerular filtration rate 
(GFR). The mechanism of this slowly pro-
gressive form of chronic renal disease is un-
clear [1]. Therefore, chronic kidney disease 
(CKD) could be evaluated by estimated GFR 
(eGFR).
In patients with SSc, Kingdon et al. 
[2] showed that eGFR calculated using the 
7-variable Modification of Diet in Renal Dis-
ease (MDRD) equation and Cockcroft-Gault 
formula correlated with GFR measured us-
ing a radioisotope clearance method. In SSc 
patients with normal serum creatinine (sCr), 
the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) is a useful formula 
to assess GFR [3].
The aim of this study was to evaluate the 
presence of renal involvement in SSc patients 
by GFR estimated by 7-variable MDRD and 
CKD-EPI equations and to correlate eGFR 
with clinical variables of the disease.
Materials and methods
150 consecutive patients who met the 
American College of Rheumatology/Eu-
ropean League Against Rheumatism Col-
laborative Initiative criteria for SSc were 
enrolled in this study [4]. Of these, 105 pa-
tients were eligible (92 female and 13 male; 
mean age 54.9 ± 14.4 years). Patients with 
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elevated sCr, elevated blood urea, urinary 
tract infection, abnormal urinary sediment, 
glomerulonephritis, kidney stones, anti-
phospholipid-associated nephropathy, dia-
betes, cardiovascular disease (hypertension, 
myocardial infarction, arrhythmias, heart 
failure), hyperlipidemia, coagulopathy, SRC, 
or smokers were excluded.
Mean duration of Raynaud’s phenom-
enon and disease were 10.4 ± 5.8 years and 
9.1 ± 5.1 years, respectively. 60 patients had 
limited cutaneous SSc and 45 had diffuse cu-
taneous SSc as defined by Le Roy et al. [5].
All SSc patients underwent treatment 
with calcium channel blockers (nifedipine 
30 mg/day). No patients were treated with 
immunosuppressive agents (e.g., cyclophos-
phamide or mycophenolate mofetil).
No patients were undergoing treatment 
with angiotensin-converting enzyme inhibi-
tors and/or angiotensin II receptor blockers. 
Three patients had elevated sCr values.
Written consent was obtained according 
to the Declaration of Helsinki and the study 
was approved by the Ethics Committee of 
Sapienza University.
Laboratory parameters
Laboratory investigations included sCr, 
blood urea nitrogen, sodium, potassium, uric 
acid, and albumin. SCr was measured using 
a Jaffe alkaline picrate assay (Abbott Aeroset 
analyzer) [6].
Calculation of GFR
GFR was calculated using the 7 variables 
developed in the MDRD study. This formula 
uses demographic and serum variables but 
does not require urine collection: GFR = 
170 × [sCr concentration (mg/dL)]–0.999 × 
(age)–0.176 × [serum urea nitrogen concentra-
tion (mg/dL)]–0.17 × [albumin concentration 
(g/dL)]0.318 × (0.762 if the patient is female) 
× (1.18 if the patient is black) [7].
CKD-EPI, expressed as a single equa-
tion, is GFR = 141 × min (sCr/k, 1)α × max 
(sCr/k, 1)–1.209 × 0.993Age × 1.018 (if fe-
male) × 1.159 (if black), where k is 0.7 for 
females and 0.9 for males, and α is –0.329 
for females and –0.411 for males (min in-
dicates the minimum of sCr/k or 1 and max 
indicates the maximum of sCr/k or 1) [8]. 
Finally, sclerodermic patients were classified 
in subgroups based on stages of renal failure 
according to the Kidney Disease Outcomes 
Quality Initiative guidelines [9].
Nailfold videocapillaroscopy
Nailfold videocapillaroscopy (NVC) 
was performed with a videocapillaroscope 
(Pinnacle Studio Version 8) equipped with a 
500× optical probe. The nailfold of the 2nd, 
3rd, 4th, and 5th finger was examined in each 
patient. According to Cutolo et al. [10], pat-
terns identified within the “SSc pattern” in-
clude early, active, and late. NVC is the best 
technique to evaluate microvascular damage 
in SSc patients.
Clinical assessment
Skin involvement was assessed using 
the modified Rodnan skin thickness score 
(mRSS), a validated measure of skin thick-
ening in SSc. In the mRSS, skin thickening 
is assessed at 17 body sites by palpation and 
rated on a scale with values of 0 (normal), 1 
(mild), 2 (moderate) or 3 (severe skin thick-
ening). The total skin score is the sum of the 
individual skin assessments in the 17 body 
areas, with a possible range of 0 to 51; the 
higher the score, the greater the extent and 
severity of skin thickening [11]. Disease ac-
tivity in SSc was measured using the Disease 
Activity Index (DAI) which consists of 10 
weighted variables: total skin score > 14, 
scleroderma, digital necrosis, arthritis, total 
lung capacity < 80%, erythrocyte sedimen-
tation rate > 30, hypocomplementemia and 
changes in cardiopulmonary, skin, and vascu-
lar symptoms in the past month [12]. Disease 
severity was measured by the Disease Sever-
ity Scale (DSS). This scale assesses disease 
severity in 9 organs or systems, namely gen-
eral health, peripheral vascular, skin, joint/
tendon, muscle and gastrointestinal tract, 
lungs, heart, and kidneys. Each organ/system 
is scored separately from 0 to 4 depending on 
whether there is no, mild, moderate, severe, 
or end-stage involvement [13].
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Statistical analysis
All results are expressed as mean and stan-
dard deviation (SD). Commercial software 
was used for statistical analysis (SPSS version 
20.0). The coefficients of skewness and kurto-
sis were used to evaluate normal distribution 
of data. Multiple regression analysis was done 
to assess the relationship between eGFR and 
demographic and clinical features (age, dura-
tion of disease, mRSS, DAI, DSS). Pearson 
product-moment correlation coefficient (r) 
was used to test for an association between 
numerical variables. Group comparisons were 
made by Student’s unpaired 2-tailed t-test. χ2- 
or Fisher’s exact tests were used to compare 
categorical variables as appropriate. A p-value 
< 0.05 was considered significant.
Results
In all patients, sCr concentrations were 
normal (0.75 ± 0.17 mg/dL). Median 24-h 
proteinuria was 125 ± 34 mg/24 h. eGFR was 
85 ± 22 mL/min and 91 ± 19 mL/min using 
7-variable MDRD and CKD-EPI equations, 
respectively. Urinalysis showed normal uri-
nary sediment in all SSc patients.
Age correlated negatively with eGFR 
when evaluated by 7-variable MDRD 
(r = –0.59, p < 0.0001) or CKD-EPI (r = –0.63, 
p < 0.0001). Duration of disease correlated 
negatively with eGFR when evaluated by 
7-variable MDRD (r = –0.29, p < 0.01) or 
CKD-EPI (r = –0.20, p < 0.05). There were 
no correlations between eGFR and mRSS, 
DAI or DSS. These data are summarized in 
Table 1.
eGFR evaluated by 7-variable MDRD 
was not significantly different (p > 0.05) in 
patients with limited cutaneous SSc (81 ± 21 
mL/min) or diffuse cutaneous SSc (90 ± 23 
mL/min). Additionally, eGFR evaluated by 
CKD-EPI was not significantly different in 
patients with limited cutaneous SSc (85 ± 17 
mL/min) or diffuse cutaneous SSc (99 ± 19 
mL/min).
Table 1. Association between estimated glomerular filtration rate (CKD-EPI and 7-variable MDRD) and 
epidemiological and clinical features of SSc patients.
CKD-EPI 7-variable MDRD
β r p-value β r p-value
Age –0.645 –0.73 < 0.0001 –0.635 –0.624 < 0.0001
Disease duration –0.365 –0.240 < 0.05 –0.345 –0.291 < 0.05
RP duration –0.152 0.298 0.08 0.102 –0.234 0.61
mRSS 0.416 0.149 0.27 –0.077 0.232 0.62
DAI 0.143 –0.330 0.07 –0.082 0.060 0.70
DSS 0.156 0.240 0.18 0.073 0.042 0.72
β = standard regression coefficient. In the analysis, the estimated glomerular filtration rate (CKD-EPI and 
7-variable MDRD) was entered as a dependent variable. The following factors were entered as indepen-
dent variables: age, disease duration, Raynaud’s phenomenon duration, mRSS, DAI, and DSS. RP = 
Raynaud’s phenomenon; mRSS = modified Rodnan skin thickness score; DAI = Disease Activity Index; 
DSS = Disease Severity Scale.
Figure 1. GFR evaluated by 7-variable MDRD and CKD-EPI equations in three capillaroscopic patterns.
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The mean value of sCr concentrations 
was significantly different in the three cap-
illaroscopic groups (p < 0.0001). The mean 
value of sCr concentrations increased with 
severity of capillaroscopic damage: early 
0.64 ± 0.15, active 0.78 ± 0.17, and late 
0.83 ± 0.14 mg/dL.
The mean value of eGFR evaluated by 
7-variable MDRD or CKD-EPI was signifi-
cantly different in the three capillaroscopic 
groups (p < 0.0001). The mean value of 
eGFR evaluated by 7-variable MDRD de-
creased with capillaroscopic damage sever-
ity: early 95 ± 16 mL/min, active 86 ± 25 
mL/min, and late 76 ± 21 mL/min. Similarly, 
eGFR evaluated by CKD-EPI decreased 
with capillaroscopic damage severity: early 
101 ± 12 mL/min, active 95 ± 17 mL/min, 
and late 82 ± 21 mL/min (Figure 1).
The mean value of eGFR evaluated by 
7-variable MDRD or CKD-EPI was sig-
nificantly different in SSc patients with or 
without digital ulcer (DU) history (Figure 
2). The mean value of eGFR evaluated by 
7-variable MDRD was significantly lower in 
SSc patients with DU history than in patients 
without DU history (74 ± 15 mL/min vs. 
97 ± 23 mL/min, p < 0.0001). eGFR evalu-
ated by CKD-EPI was significantly lower in 
SSc patients with DU history than in patients 
without (80 ± 17 mL/min vs. 105 ± 12 mL/
min, p < 0.0001) (Figure 2). Conversely, sCr 
concentrations were significantly higher in 
SSc patients with DU history than in patients 
without (0.83 ± 0.20 mL/min vs. 0.68 ± 0.10 
mL/min, p < 0.0001).
Discussion
This study evaluated GFR by the MDRD 
and CKD-EPI equations in SSc patients 
without clinical renal involvement. The 
MDRD formula underestimated GFR com-
pared to CKD-EPI. MDRD has been validat-
ed in patients with kidney impairment while 
CKD-EPI has been used in different popula-
tions, including healthy subjects. The CKD-
EPI equation has shown better performance 
in the higher ranges of GFR [7, 8]. Recently, 
Tent et al. [14] retrospectively evaluated the 
use of MDRD and CKD-EPI to monitor the 
long-term course of kidney function and to 
identify individuals with progressive kidney 
function loss. In their study, sCr at baseline 
was 1.30 ± 0.52, MDRD was 63 ± 24, and 
CKD-EPI was 70 ± 26. This shows accept-
able performance of the CKD-EPI equation 
and a slight underestimation of mean func-
tion loss by the MDRD formula in the long-
term follow-up of CKD patients.
GFR in patients with SSc appears to be 
normal or slightly reduced. The two formu-
las (7-variable MDRD and CKD-EPI) were 
found to be excellent indicators of renal 
function in patients with SSc.
Although age represents an independent 
risk factor for the reduction of eGFR, our study 
showed a negative correlation with disease du-
ration. We can assume that eGFR, regardless of 
age, decreases with disease duration which in 
turn increases renal vascular damage.
We demonstrated that eGFR correlated 
negatively with severity of microvascular 
digital damage evaluated by NVC. eGFR 
was also lower in patients with a history of 
DUs than in those without.
Figure 2. GFR evaluated by 7-variable MDRD and CKD-EPI equations in SSc patients with or without 
digital ulcer history.
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Many complications of SSc are vascular, 
including pulmonary arterial hypertension 
and SRC. Structural vascular damage occurs 
in many vascular beds concurring to pul-
monary, renal, cardiac, and gastrointestinal 
complications [15]. In contrast to other SSc 
complications, renal involvement is asymp-
tomatic with the exception of SRC [16]. A 
significant reduction in renal blood flow and 
elevated plasma renin activity was found in 
SSc patients with normal filtration [17]. Au-
topsy studies have demonstrated renal histo-
pathologic changes in the majority of patients 
with SSc in which SRC and hypertension 
have not developed. Subintimal proliferation 
and luminal narrowing of small- and medi-
um-sized arteries in the kidney are the most 
prominent findings. Arterial changes coexist 
with varying degrees of tubule atrophy, inter-
stitial fibrosis, and glomerular obsolescence.
Intrarenal vascular damage is present ear-
ly on in SSc without clinical renal involve-
ment. In a previous study, Rosato et al. [18] 
demonstrated that intrarenal arterial stiffness 
was higher in SSc patients than in healthy 
controls and correlated with severity of 
capillaroscopic damage. Intrarenal stiffness 
showed a negative correlation with eGFR. 
The authors demonstrated that Doppler in-
dices of intrarenal stiffness were reliable 
markers to predict the occurrence of new 
DUs. The pathophysiological mechanism of 
this slowly progressive form of chronic re-
nal disease in SSc is unclear. Reduced renal 
blood flow plays a key role in the reduction 
of GFR. In all renal manifestations of SSc, 
chronic renal vasculopathy seems to be the 
main pathogenic mechanism. We can sup-
pose that, in the initial phases of renal dam-
age progression, resistance indices increase 
and GFR is normal or slightly reduced. This 
initial reduction of GFR is linked more to re-
duced blood inflow to intrarenal vessels than 
to reduced glomerular filtration capacity [19, 
20]. GFR is further reduced with the progres-
sion of intrarenal vascular damage. The dete-
rioration of GFR is due both to the reduction 
in intrarenal arteries blood inflow and glo-
merular injury. Secondary ischemic changes 
in the glomeruli may occur with the progres-
sion of renal ischemic injury. Glomerular 
injury is the determining factor in the onset 
of pathological urinary sediment (hematuria 
and proteinuria) and increased sCr. The rel-
evant factors mediating vascular changes in 
SSc include the renin-angiotensin system, 
profibrotic growth factors, transforming 
growth factor-β, connective tissue growth 
factor, and reactive oxygen species [21]. In a 
recent study, we demonstrated that intrarenal 
arterial elasticity showed a linear correlation 
with sympathetic activity in a group of SSc 
patients with normal sCr and high renal re-
sistive index [22].
We can conclude that in SSc patients with-
out renal involvement, eGFR decreases with 
severity of digital vascular damage. We can 
hypothesize that renal vascular damage, simi-
lar to Raynaud’s phenomenon, represents the 
pathogenetic mechanism of the reduction of 
eGFR in early stages of the disease.
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